Drug Detail:Goserelin implant (Goserelin (implant) [ goe-se-rel-in ])
Drug Class: Gonadotropin releasing hormones Hormones / antineoplastics
Usual Adult Dose for Prostate Cancer
For the palliative treatment of advanced carcinoma of the prostate:
3.6 mg or 10.8 mg subcutaneously into the upper abdominal wall once
The 3.6 mg dosage may be repeated every 28 days.
The 10.8 mg dosage may be repeated every 12 weeks.
Intended for long-term administration unless clinically inappropriate.
Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy): Males: SubQ:
Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant
OR
28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses (2 depots preceding and 2 during radiotherapy)
Uses:
- In combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment should start 8 weeks prior to radiation therapy and continue during radiation.
- For palliative treatment of advanced carcinoma of the prostate.
Usual Adult Dose for Endometriosis
3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days
The recommended duration of therapy is 6 months.
Use: For the management of endometriosis, including pain relief and reduction of endometriotic lesions.
Usual Adult Dose for Breast Cancer-Palliative
For use in the palliative treatment of advanced breast cancer: 3.6 mg subcutaneously into the upper abdominal wall once; repeat every 28 days
Intended for long-term administration unless clinically inappropriate.
Use: For the palliative treatment of advanced breast cancer in pre- and perimenopausal women
Usual Adult Dose for Bleeding
1 or 2 of the 3.6 mg subcutaneous depot injections (with each depot given 4 weeks apart). When 1 depot is administered, surgery should be performed at 4 weeks. When 2 depots are administered, surgery should be performed within 2 to 4 weeks following administration of the second depot.
Use: For use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
No adjustment recommended.
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to the active component or any of the ingredients
- Pregnancy
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Caution should be taken while inserting the implant into the interior abdominal wall due to the proximity of underlying inferior epigastric artery and its branches
- Caution should be taken when administering this drug to patients with a low BMI and/or who are receiving full anticoagulation medication.